Naloxone B. Braun Melsungen (Naloxone Hydrochloride)

Naloxone works by competitively binding to μ‑opioid receptors in the central nervous system. It displaces opioid agonists without activating the receptors, thereby blocking opioid‑mediated suppression of the respiratory drive and quickly restoring ventilation.

The specific dose of Naloxone B. Braun Melsungen is determined by the prescribing clinician based on the patient’s condition, the opioid involved, and the route of administration. Standard practice often starts with a low dose that can be repeated, but exact dosing must follow the prescriber’s order.

Safety data for naloxone in pregnancy and lactation are limited. Because naloxone does not cross the placenta in significant amounts and is not expected to be secreted in breast milk, it is generally considered acceptable when the benefits of treating a life‑threatening opioid overdose outweigh potential risks. Clinical judgment is required.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Naloxone is the most widely used opioid antagonist and is comparable to other agents such as nalmefene or naltrexone. Compared with nalmefene, naloxone has a faster onset and shorter duration, making it preferred for emergency reversal, whereas nalmefene may be used for longer‑acting blockade in certain clinical settings.

Naloxone B. Braun Melsungen should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

Naloxone is administered by intramuscular or intravenous injection. The appropriate route and injection site are selected by the healthcare professional based on the clinical situation, and the drug is given as a rapid bolus to achieve immediate effect.

Serious risks include severe hypertension, cardiac arrhythmias, seizures, pulmonary edema, and rare anaphylactic reactions. Rapid reversal of opioid effects can also precipitate acute opioid withdrawal, which may be distressing and require monitoring.

Naloxone is contraindicated in individuals with a known hypersensitivity to naloxone or any component of the formulation. Caution is advised in patients with severe cardiovascular disease, as rapid reversal may cause abrupt changes in blood pressure.